Clinical and Scientific Publications

  1. Tong TML, Burgmans MC, Speetjens FM, et al. Combining melphalan percutaneous hepatic perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: first safety and efficacy data from the phase Ib part of the Chopin trial. Cardiovasc Intervent Radiol. 2023;46:350–359. doi: 10.1007/s00270-022-03338

  2. Dewald CLA, Becker LS, Meine TC, et al. New perspectives in unresectable cholangiocarcinoma? Evaluation of chemosaturation with percutaneous hepatic perfusion as a palliative treatment option. Clin Exp Metastasis. 2023;40:95–104. doi: 10.1007/s10585-022-10193-4

  3. Tong TML, Samim M, Kapiteijn E, et al. Predictive parameters in patients undergoing percutaneous hepatic perfusion with melphalan for unresectable liver metastases from uveal melanoma: a retrospective pooled analysis. Cardiovasc Intervent Radiol. 2022;45(9):1304–1313. doi: 10.1007/s00270-022-03225-9

  4. Tong TML, Burgmans MC, Speetjens FM, et al. Safety and efficacy of combined melphalan percutaneous hepatic perfusion (M-PHP) and ipilimumab plus nivolumab (IPI+NIVO) in metastasized uveal melanoma (mUM): first results of the phase Ib part of the CHOPIN trial. J Clin Oncol. 2022;40:16(suppl):9560. doi: 10.1200/JCO.2022.40.16_suppl.9560

  5. Zager JS, Orloff MM, Ferrucci PF, et al. FOCUS phase 3 trial results: percutaneous hepatic perfusion (PHP) with melphalan for patients with ocular melanoma liver metastases (PHP-OCM-301/301A). J Clin Oncol. 2022;40:16(suppl):9510. doi: 10.1200/JCO.2022.40.16_suppl.9510

  6. Modi S, Gibson T, Vigneswaran G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma. Melanoma Res. 2022;32(2):103–111. doi: 10.1097/CMR.0000000000000806

  7. Veelken R, Maiwald B, Strocka S, et al. Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers. Cardiovasc Intervent Radiol. 2022;45:218–222. doi: 10.1007/s00270-021-02983-2

  8. Yu J, Green MD, Li S, et al. Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination. Nat Med. 2021;27:152–164. doi: 10.1038/s41591-020-1131-x

  9. Ferrucci PF, Cocorocchio E, Bonomo G, Varano GM, Della Vigna P, Orsi F. A new option for the treatment of intrahepatic cholangiocarcinoma: percutaneous hepatic perfusion with CHEMOSAT delivery system. Cells. 2021;10(1):70. doi: 10.3390/cells10010070

  10. Lee JC, Mehdizadeh S, Smith J, et al. Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis. Sci Immunol. 2020;5:eaba0759. doi:10.1126/sciimmunol.aba0759

  11. Brüning R, Tiede M, Schneider M, et al. Unresectable hepatic metastasis of uveal melanoma: hepatic chemosaturation with high-dose melphalan—long-term overall survival negatively correlates with tumor burden. Radiol Res Pract. 2020;2020:5672048. doi: 10.1155/2020/5672048

  12. Meijer TS, Burgmans MC, de Leede EM, et al. Percutaneous hepatic perfusion with melphalan in patients with unresectable ocular melanoma metastases confined to the liver: a prospective phase II study. Ann Surg Oncol. 2021;28:1130–1141. doi: 10.1245/s10434-020-08741-x

  13. Schönfeld L, Hinrichs JB, Marquardt S, et al. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma. J Cancer Res Clin Oncol. 2020;146:3003–3012. doi: 10.1007/s00432-020-03289-5

  14. Erinjeri JP, Fine GC, Adema GJ, et al. Immunotherapy and the interventional radiologist: challenge and opportunities—a society of interventional oncology white paper. Radiology. 2019;292(1):25–34. doi: 10.1148/radiol.2019182326

  15. Artzner C, Mossakowski O, Hefferman G, et al. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience. Cancer Imaging. 2019;19:31. doi: 10.1186/s40644-019-0218-4

  16. Meijer TS, Burgmans MC, Fiocco M, et al. Safety of percutaneous hepatic perfusion with melphalan in patients with unresectable liver metastases from ocular melanoma using the Delcath systems’ second-generation hemofiltration system: a prospective non-randomized phase II trial. Cardiovasc Intervent Radiol. 2019;42:841–852. doi: 10.1007/s00270-019-02177-x

  17. Marquardt S, Kirstein MM, Brüning R, et al. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival. Eur Radiol. 2019;29:1882–1892. doi: 10.1007/s00330-018-5729-z

  18. Karydis I, Gangi A, Wheater MJ, et al. Percutaneous hepatic perfusion with melphalan in uveal melanoma: a safe and effective treatment modality in an orphan disease. J Surg Oncol. 2018;117:1170–1178. doi: 10.1002/jso.24956

  19. Vogel A, Gupta S, Zeile M, et al. Chemosaturation percutaneous hepatic perfusion: a systematic review. Adv Ther. 2016;33:2122–2138. doi: 10.1007/s12325-016-0424-4